|1.||Iwamoto, Jun: 17 articles (03/2012 - 01/2002)|
|2.||Takeda, Tsuyoshi: 14 articles (03/2012 - 01/2002)|
|3.||Adachi, J D: 9 articles (02/2006 - 01/2000)|
|4.||Sato, Yoshihiro: 8 articles (03/2012 - 04/2004)|
|5.||Ichimura, Shoichi: 7 articles (03/2004 - 01/2002)|
|6.||Uzawa, Mitsuyoshi: 6 articles (01/2011 - 01/2003)|
|7.||Vestergaard, P: 5 articles (07/2014 - 09/2010)|
|8.||Endo, Yasuo: 5 articles (06/2013 - 04/2010)|
|9.||Sugawara, Shunji: 5 articles (06/2013 - 04/2010)|
|10.||Nagashima, Masakazu: 5 articles (01/2012 - 03/2003)|
01/01/2012 - "The 3-year course of etidronate therapy also resulted in marked improvement of the severe osteoporosis and the patient was able to return to work and enjoy a normal life. "
12/15/1994 - "Etidronate may be especially beneficial in severe osteoporosis with marked loss of bone and multiple vertebral crush fractures. "
06/01/1997 - "The effect of combination treatment with NaF and etidronate on the BMD of the lumbar spine in corticosteroid treated patients with established osteoporosis is superior to that of etidronate alone."
01/01/2003 - "There were fewer new fractures in group 2 than in group 1. Treatment with etidronate is effective in patients with glucocorticoid-induced osteoporosis."
08/01/2002 - "It was shown that cyclical etidronate therapy is effective for steroid induced osteoporosis."
08/01/1992 - "Intermittent cyclical therapy with etidronate has been shown to be effective for postmenopausal osteoporosis in two controlled studies. "
05/01/2000 - "Cyclical etidronate has been shown to be effective in the treatment of established postmenopausal osteoporosis but less is known about its effects on early menopausal bone loss. "
12/01/1997 - "Long-term cyclical etidronate is a safe, effective, and well-tolerated treatment for postmenopausal osteoporosis. "
01/01/1991 - "Intermittent cyclic etidronate treatment may be effective in preventing bone loss and in decreasing the risk of trabecular plate perforation, and thereby maintaining the integrity of bone architecture, in postmenopausal osteoporosis.(ABSTRACT TRUNCATED AT 250 WORDS)"
10/01/1997 - "Long-term efficacy of cyclical etidronate therapy in postmenopausal osteoporosis."
05/01/1997 - "The efficacy of treatment was assessed by a) a pain and performance questionnaire that patients were asked to complete daily and b) a CT scan comparison of a randomly preselected osseous lesion before and 30 weeks after Re-186-HEDP i.v. application. "
09/01/2007 - "The aim of this study was to evaluate the efficacy of a systemic application of rhenium-186 hydroxyethylidenediphosphonate (Re HEDP) for pain treatment in patients with hemophilic arthropathies. "
12/01/1995 - "Three cases are presented in which the use of the bisphosphonate etidronate allowed for a reduction in opiate use with improvement in pain control and preservation of cognitive function. "
09/16/1989 - "[Efficacy of oral etidronic acid on pain and hypocalciuria in myeloma]."
09/01/2007 - "The results of this study show an improvement of the pain symptoms of the involved joints 12 weeks after therapy with Re HEDP in patients with hemophilic arthropathy. "
|4.||Hypercalcemia (Milk Alkali Syndrome)
06/01/2014 - "This case provides further evidence of etidronate as an alternative and effective treatment for moderate-severe hypercalcemia. "
02/23/1987 - "Intravenous etidronate is apparently an effective and safe treatment for neoplastic hypercalcemia."
03/01/1985 - "Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease."
02/23/1987 - "These studies of etidronate in hypercalcemia suggest the response is sustained for several weeks."
01/01/1987 - "As part of a multicenter trial of etidronate disodium for control of hypercalcemia in patients with malignancies, patients achieving normocalcemia within seven days after starting intravenous therapy with etidronate disodium plus saline were enrolled into a double-blind, placebo-controlled trial of oral etidronate disodium to maintain normocalcemia. "
|5.||Neoplasm Metastasis (Metastasis)
01/01/1991 - "In the EHDP-treated mice, there was no significant reduction in the incidence of bone metastasis, the size of the lesions, or the number of bone lesions per mouse. "
11/01/2001 - "Rhenium-188 hydroxyethylidine diphosphonate (HEDP) is a new and attractive radiopharmaceutical that localizes in skeletal metastases and emits beta particles that may be therapeutically beneficial. "
06/01/2000 - "Quantifying leukocyte and thrombocyte suppression-recovery after Re-186 HEDP for bone metastases."
05/07/2000 - "Seven patients (pts) with multiple painful bone metastases were treated with Re-188 HEDP. "
11/01/1999 - "But, it is necessary to add carrier when preparing Re-188 HEDP for the treatment of bone metastases."
|1.||Alendronate (Alendronate Sodium)
|3.||risedronic acid (risedronate)
|5.||Etidronic Acid (HEDP)
|6.||Calcitonin (Calcitonin, Eel)
|8.||Cholecalciferol (Vitamin D3)
|10.||Clodronic Acid (Clodronate)
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)